Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis
July 06 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced four
poster presentations on marzaptacog alfa (activated) (MarzAA) and
dalcinanonog alfa (DalcA) at the upcoming International Society on
Thrombosis and Haemostatis (ISTH) Virtual Congress being held from
July 17-21, 2021.
Poster TitleDose selection for subcutaneous
marzaptacog alfa (activated) in subjects with Factor VII deficiency
using population pharmacometrics clinical trial
simulationsAuthorTom Knudsen, D.V.M., Ph.D., vice
president, corporate development, Catalyst Biosciences
Poster titleDose selection of marzaptacog alfa
(activated) in children with Hemophilia: a population
pharmacokinetic exposure matching
strategyAuthorTom Knudsen, D.V.M., Ph.D., vice
president, corporate development, Catalyst Biosciences
Poster titleSubcutaneous marzaptacog alfa
(activated) is effective treatment of bleeding in FVII deficient
ratsAuthorTom Knudsen, D.V.M., Ph.D., vice
president, corporate development, Catalyst Biosciences
Poster titleMitigation of injection site
reactions after subcutaneous administration of dalcinanonog alfa
(DalcA) in Hemophilia B using preclinical
modelsAuthorNatacha Le Moan, senior director,
translational research, Catalyst Biosciences
A copy of the presentation materials can be accessed on
the Events and Presentations section of the Catalyst
website once the congress begins.
About Catalyst Biosciences, the Protease
Medicines companyCatalyst is a research and clinical
development biopharmaceutical company focused on addressing unmet
medical needs in rare disorders of the complement and coagulation
systems. Our protease engineering platform has generated two
late-stage clinical programs, including MarzAA, a SQ-administered
next-generation engineered rFVIIa for the episodic treatment of
bleeding in subjects with rare bleeding disorders and dalcinonacog
alfa (DalcA) a SQ-administered next-generation engineered rFIX for
prophylaxis of bleeding in subjects with Hemophilia B. Our
complement pipeline includes a preclinical C3-degrader program
licensed to Biogen for dry age-related macular degeneration, an
improved complement factor I protease for SQ replacement therapy in
patients with CFI deficiency, and C4b-degraders designed to target
disorders of the classical complement pathway, as well as other
complement programs in discovery.
Forward-Looking Statements This
press release contains forward-looking statements that involve
substantial risks and uncertainties. Forward-looking statements
include statements about the potential benefits of products based
on Catalyst's engineered protease platform. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially, including, but not limited to, the
risk that the one or both of the clinical trials of MarzAA may be
delayed or terminated as a result of COVID-19, competitive products
and other factors, that trials may not have satisfactory outcomes,
that additional human trials will not replicate the results from
earlier trials, that potential adverse effects may arise from the
testing or use of MarzAA, including the generation of neutralizing
antibodies, the risk that costs required to develop or manufacture
the Company's products will be higher than anticipated, including
as a result of delays in trial enrollment, development and
manufacturing resulting from COVID-19 and other factors,
competition and other risks described in the "Risk Factors" section
of the Company's Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission on May 6,
2021, and in other filings with the Securities and Exchange
Commission. The Company does not assume any obligation to update
any forward-looking statements, except as required by law.
Contact:Ana KaporCatalyst
Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024